- Conditions
- Nail Psoriasis
- Interventions
- Deucravacitinib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced May 22, 2026, 1:34 AM EDT